Effect of age and smoking on in vivo CYP1A2, flavin‐containing monooxygenase, and xanthine oxidase activities in Koreans: Determination by caffeine metabolism

To assess the effect of gender, age, and smoking habits on the in vivo activities of CYP1A2, flavin‐containing monooxygenase (FMO), and xanthine oxidase in Korean subjects.

[1]  G. Kearns,et al.  Quantitation of three‐month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N‐acetyltransferase‐2, and xanthine oxidase activity determined with caffeine phenotyping , 1998, Clinical pharmacology and therapeutics.

[2]  G. Tucker,et al.  Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. , 1996, Pharmacogenetics.

[3]  F. Kadlubar,et al.  Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. , 1997, Mutation research.

[4]  D. Grant,et al.  Effect of allopurinol on caffeine disposition in man. , 1986, British journal of clinical pharmacology.

[5]  K. Itagaki,et al.  Species and sex differences in expression of flavin-containing monooxygenase form 3 in liver and kidney microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[6]  K. Brøsen,et al.  Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. , 1996, Therapeutic drug monitoring.

[7]  M A Butler,et al.  Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. , 1992, Environmental health perspectives.

[8]  Y. Cha,et al.  Oxidation of caffeine to theobromine and theophylline is catalyzed primarily by flavin-containing monooxygenase in liver microsomes. , 1997, Biochemical and biophysical research communications.

[9]  D. Ziegler.  Bioactivation of xenobiotics by flavin-containing monooxygenases. , 1991, Advances in experimental medicine and biology.

[10]  A. Astier,et al.  Noninterference of cytochrome P4501A2 in the cytotoxicity of tacrine using genetically engineered V79 Chinese hamster cells for stable expression of the human or rat isoform and two human hepatocyte cell lines. , 1997, Biochemical pharmacology.

[11]  D. Ziegler,et al.  Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. , 1988, Drug metabolism reviews.

[12]  O. Saugstad,et al.  Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. , 1996, Pediatrics.

[13]  L. Le Marchand,et al.  Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol. , 1997, Pharmacogenetics.

[14]  M. Relling,et al.  Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 * activities , 1992, Clinical pharmacology and therapeutics.

[15]  P. Boyle,et al.  Time trend and age‐period‐cohort effect on incidence of bladder cancer in Connecticut, 1935–1992 , 1996, International journal of cancer.

[16]  M. Nakano,et al.  Effects of antiasthma drugs on superoxide anion generation from human polymorphonuclear leukocytes or hypoxanthine-xanthine oxidase system. , 1991, International archives of allergy and applied immunology.

[17]  J. Idle,et al.  TRIMETHYLAMINURIA (FISH-ODOUR SYNDROME): AN INBORN ERROR OF OXIDATIVE METABOLISM , 1987, The Lancet.

[18]  C. Cazeneuve,et al.  Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. , 1994, British journal of clinical pharmacology.

[19]  D. Schrenk,et al.  A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers , 1998, European Journal of Clinical Pharmacology.

[20]  S. Spielberg,et al.  A urinary metabolite ratio that reflects systemic caffeine clearance , 1987, Clinical pharmacology and therapeutics.

[21]  L. Fabbri,et al.  Xanthine oxidase activity in bronchoalveolar lavage fluid from patients with chronic obstructive pulmonary disease. , 1996, Free radical biology & medicine.

[22]  T. Kamataki,et al.  Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  D. Silverman,et al.  A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  Tanaka.  In vivo age‐related changes in hepatic drug‐oxidizing capacity in humans , 1998, Journal of clinical pharmacy and therapeutics.

[25]  Phenotyping of flavin-containing monooxygenase using caffeine metabolism and genotyping of FMO3 gene in a Korean population. , 1999, Pharmacogenetics.

[26]  M. L. Bernal,et al.  Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  C. Masimirembwa,et al.  Low CYP1A2 activity in rural Shona children of Zimbabwe , 1995, Clinical pharmacology and therapeutics.

[28]  H. Roh,et al.  Involvement of CYP3A1, 2B1, and 2E1 in C-8 hydroxylation and CYP 1A2 and flavin-containing monooxygenase in N-demethylation of caffeine; identified by using inducer treated rat liver microsomes that are characterized with testosterone metabolic patterns. , 1998, Chemico-biological interactions.

[29]  R. Hayes,et al.  Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. , 1992, Pharmacogenetics.